Yong-Jin Wu

This inventor holds 45 USPTO granted patents and 6 published patent applications and 8 EPO patents, primarily in Kinase Inhibitors. Top assignees: Bristol-Myers Squibb Compnay, Pfizer Corporation, Vanderbilt University. Active years: 2000-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Yong-Jin Wu. Retrieved from https://idiyas.com/inventor/yong-jin-wu

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 45 (Patent Applications = 6)

% Patents Active = 93.3

EPO Patents = 8 (Patent Applications = 11)

Average Co-Inventor Count = 2.4

ph-index = 8

Forward Citations = 223(Granted Patents)

Location History:

East Lyme, CT (US) (2000 - 2002)
Princeton, NJ (US) (2019 - 2020)
Madison, CT (US) (2001 - 2023)

Company Filing History:

28 out of 3,742

Bristol-Myers Squibb Compnay

Vanderbilt University

patents

4. 1 out of 41

Bristol Meyers Squibb Company

patents

Years Active: 2000-2024

Loading Chart...

Areas of Expertise:

Kinase Inhibitors

Beta-Amyloid Production

Potassium Channel Openers

mGluR4 Potentiators

BACE1 Inhibitors

NK-1 Antagonists

Aminopyrrolotriazines

Triazolopyridinyl Compounds

Cycloalkylamine Derivatives

Thiazole Derivatives

Erythromycin Derivatives

5-HT6 Antagonists

45 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12110290 - Triazolopyridinyl compounds as kinase inhibitors (2024-10-08),

2. 11767322 - Triazolopyridinyl compounds as kinase inhibitors (2023-09-26),

3. 11618753 - Aminopyrrolotriazines as kinase inhibitors (2023-04-04),

4. 10836758 - Acyl sulfonamide NaV1.7 inhibitors (2020-11-17),

5. 10526323 - Indazole and azaindazole substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction (2020-01-07),

6. 10227343 - Isoquiniline and napthalene-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction (2019-03-12),

7. 9475784 - 4,6-diarylaminothiazines as BACE1 inhibitors and their use for the reduction of beta-amyloid production (2016-10-25),

8. 8710061 - Compounds for the reduction of β-amyloid production (2014-04-29),

9. 8637525 - Compounds for the reduction of beta-amyloid production (2014-01-28),

10. 8637523 - Compounds for the reduction of beta-amyloid production (2014-01-28),

11. 8604024 - Compounds for the reduction of beta-amyloid production (2013-12-10),

12. 8598161 - Compounds for the reduction of beta-amyloid production (2013-12-03),

13. 8486952 - Compounds for the reduction of β-amyloid production (2013-07-16),

14. 8349880 - Bicyclic compounds for the reduction of beta-amyloid production (2013-01-08),

15. 7772221 - Diaminopropane derived macrocycles as inhibitors of β amyloid production (2010-08-10),

Title: **Yong-Jin Wu: A Pioneer in Kinase Inhibitor Research**

Introduction

Yong-Jin Wu, a prominent inventor based in Madison, CT, has made significant contributions to the field of pharmacology through his innovative work on kinase inhibitors. With an impressive portfolio of 43 patents, Wu's research has played a pivotal role in advancing therapeutic options for various diseases.

Latest Patents

Among his latest inventions are his patents on triazolopyridinyl compounds as kinase inhibitors. These compounds, characterized by the formula (I) along with their enantiomers, diastereomers, stereoisomers, and pharmaceutically acceptable salts, serve as crucial kinase modulators. Notably, these compounds have shown potential in modulating RIPK1, which is important for therapeutic applications.

Career Highlights

Wu's distinguished career includes significant positions at major pharmaceutical companies. He worked at Bristol-Myers Squibb Company, where he contributed to various drug development projects. He also held a position at Pfizer Corporation, further enhancing his expertise in innovative chemical compounds and their applications in drug discovery.

Collaborations

Throughout his career, Yong-Jin Wu has collaborated with notable professionals, including Jason M. Guernon and Huan He. Their teamwork has led to advancements in the research and development of new therapeutic agents, showcasing the importance of collaboration in scientific research.

Conclusion

Yong-Jin Wu stands out as a leading inventor in the field of kinase inhibitors. His extensive patent portfolio reflects his dedication to innovating new treatments that have the potential to improve patient outcomes. With his continued contributions, Wu remains a key figure in the scientific community.

Profile summary based on public USPTO records.